Abstract
Correction to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.
Cite
CITATION STYLE
Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., … Lane, R. M. (2024, January 1). Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3). Nature Medicine. Nature Research. https://doi.org/10.1038/s41591-023-02639-3
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
